MMAE (Monomethyl auristatin E) CAS:474645-27-7 is a synthetic antineoplastic agent that acts as a potent mitotic inhibitor by inhibiting tubulin polymerization. Unable to be used as a drug by itself due to its toxicity, it is a very potent anti-mitotic agent that inhibits cell division by blocking the polymerization of tubulin. Widely used as the cytotoxic component of antibody-drug conjugates (ADCs) for the treatment of many different cancer types.
MMAE(Monomethyl auristatin E) is a potent cytotoxic agent that belongs to the class of auristatin compounds. It contains a sulfhydryl functional group (-SH) that can be used for the attachment of MMAE to targeting molecules such as antibodies, peptides, or small molecules.
MMAE has gained significant attention in pharmaceutical research and development due to its high potency against cancer cells. Its cytotoxic activity is based on the ability to bind to tubulin, which is an essential component of the cytoskeleton in cells. By binding to tubulin, MMAE prevents microtubule formation, which is necessary for cell division and proliferation. As a result, MMAE leads to cell cycle arrest and induces apoptosis in cancer cells.
MMAE has been successfully conjugated to monoclonal antibodies, such as trastuzumab, to create antibody-drug conjugates (ADCs) for cancer therapy. These ADCs deliver MMAE specifically to cancer cells, sparing healthy tissues from the cytotoxic effects. This approach has shown great potential for the treatment of various types of cancer, including breast, lung, and lymphoma.
AxisPharm offers 5000+ PEG Linkers with high purity. Different kinds of PEG Reagents may be available by custom synthesis.
